NeuroOne Medical Technologies Corporation reported its financial results for the full year ending September 30, 2025. License revenue was USD 3.0 million for the period, primarily related to the distribution license granted to Zimmer for the OneRF Ablation System in October 2024. Cost of product revenue included manufacturing and materials costs, as well as royalty fees of approximately USD 150 thousand for the year. Selling, general and administrative expenses totaled USD 7.4 million for the same period. The company stated that it expects to satisfy its short-term and long-term obligations through cash on hand and revenue from commercial sales.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neuroone Medical Technologies Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-122390), on December 17, 2025, and is solely responsible for the information contained therein.